Too cheap to be true The BMI scale is a cheap and accessible starting point to prevent disease
"Deposition of visceral fat around organs such as the liver and the pancreas leads to insulin resistance, pre-diabetes, and Type 2 diabetes. Unfortunately, it is challenging to measure visceral fat, and this is why, as clinicians, we use additional measures to supplement BMI, such as waist circumference, which correlates with visceral fat and can provide clinical clues to the presence of a metabolic disease such as Type 2 diabetes.
Two individuals from different ethnic backgrounds can have the same BMI but different amounts of visceral fat, hence we need to individualise screening and use additional measures such as waist circumference and consider factors such as ethnicity to look for the metabolic sequelae of obesity."
By the way one could argue that the stock price is also too cheap to be true. In my mind I always thought the perception of the "huge" cost of the oncology trial and the risks associated with "wasted money" was putting folks off from investing in the company but they clearly said the remaining costs of the current clinical trial is about $4/5 millions which is already accounted for in 2023/2024 budget! But it seems like no one is paying attention or believes. Obviously so far insiders haven't bought "cheap" shares and still are compensated as this company was a multi 6 figure million dollar company so at the bare minimum please go out there and try to find those mom and dad investors and try seriously hard to explain/convince them about the financial position of the company and the embodied value of the science. The low volume resulting in volatility due to lack of activity, trading and investing is not going anywhere unless the company understands the true value of well thought and very current strategic marketing. It's a very lazy way of trying to reach investors through a hand full analysts and that's where they are now unknown, misunderstood and ignored by the market.